Beyond the Fingerstick: Navigating CGM and BGM Decisions in GLP-1 Clinical Trials
Karl McEvoy, PhD, and Aubrey Verna share expert insights on how sponsors can balance the benefits and limitations of blood glucose meters (BGM) and continuous glucose monitors (CGM) in today’s GLP-1 trials—and why advanced eCOA platforms are critical for managing the resulting data at scale.
Karl McEvoy, PhD, Vice President, eCOA and Patient Technologies, YPrime
Aubrey Verna, Senior Product Director, YPrime
As GLP-1 therapies expand into obesity, cardiovascular disease, and rare conditions, trial teams face critical decisions on how to capture glucose data. While BGM remains the regulatory gold standard, CGM is gaining momentum for exploratory endpoints and safety monitoring. In practice, many trials now rely on both—BGM for verification and CGM for continuous insight.
In this Applied Clinical Trials article, McEvoy and Verna break down key considerations for study design, including endpoints, patient burden, geographic logistics, cost, and data infrastructure. They highlight how modern eCOA platforms turn high-volume data into actionable insights through seamless device integration, triggered diaries, and near real-time monitoring dashboards.